Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.

Who May Be Eligible (Plain English)

Who May Qualify: - Adult patients aged between 18 and 90 years of age - Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%) - Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure Who Should NOT Join This Trial: - Unable to interrupt VKA anticoagulation - Point of care International Normalized Ratio (INR) \> 1.5 - Pregnant patients - Acute hospitalization or decompensation within 2 weeks prior to study date - Participation in a study involving an investigational drug within 4 weeks prior to study date - Inability to lie flat in the supine position - Symptomatic hemodynamic instability at rest or during the procedure Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adult patients aged between 18 and 90 years of age * Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%) * Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure Exclusion Criteria: * Unable to interrupt VKA anticoagulation * Point of care International Normalized Ratio (INR) \> 1.5 * Pregnant patients * Acute hospitalization or decompensation within 2 weeks prior to study date * Participation in a study involving an investigational drug within 4 weeks prior to study date * Inability to lie flat in the supine position * Symptomatic hemodynamic instability at rest or during the procedure

Locations (1)

Johns Hopkins Hospital
Baltimore, Maryland, United States